Detecting ovarian cancer (OC) early using existing biomarkers, for example, cancer antigen 125 (CA125), is challenging due to its ubiquitous expression in many tissues. Doppel, a prion‐like protein, expresses in the male reproductive organ but is absent in female reproductive systems and healthy tissues, but plays an important role in neo‐angiogenesis. Here, we have shown two platforms, soluble Doppel in sera/ascites and Doppel expressed in circulating tumor cells ( Dpl+ CTC) in the whole blood, to detect subsets of epithelial OC (EOC). Increased levels of Doppel in the sera of OC patients, in three different cohorts, confirm Doppel as an OC‐specific biomarker. Serum Doppel levels can distinguish OC with high sensitivity and specificity (sensitivity = 0.91 and specificity = 0.89) and can also detect early‐stage HGSOCs (FIGO stages I and II) from non‐cancerous conditions with high sensitivity and specificity (sensitivity = 0.94 and specificity = 0.83). Moreover, significantly higher Doppel expression is observed in all EOC subtypes except clear cell OC. Stratifying the EOCs based on Doppel levels, we categorized them into Doppel‐high (Dpl hi ) and Doppel‐low (Dpl low ) groups. Using ascites‐derived organoids, made from Dpl hi and Dpl low patients, we identify that Doppel induces epithelial–mesenchymal transition (EMT). Doppel levels in the sera/ascites correlate with the changes in Dpl+ CTC number in whole blood, highlighting the association of Doppel‐induced EMT with CTC dissemination in the circulation. Thus, Doppel‐based detection of EOC subtypes could be a promising platform as a clinical biomarker and link the Doppel axis with OC dissemination.
Detecting ovarian cancer (OC) early using existing biomarkers, e.g., cancer antigen 125 (CA125), is challenging due to its ubiquitous expression in many tissues. Doppel, a prion-like protein, expresses in male reproductive organ but absent in female reproductive systems and healthy tissues, but plays an important role in neoangiogenesis. Here, we have shown two platforms, soluble Doppel in sera/ascites and Doppel expressed circulating tumor cells ( Dpl+ CTC) in the whole blood, to detect subsets of epithelial OC (EOC). Increased level of Doppel in the sera of OC patients, in three different cohorts, confirm Doppel as OC specific biomarker. Serum Doppel level distinguishes EOC subtypes and early stages HGSOCs from non-cancerous conditions with high sensitivity and specificity. Stratifying the EOCs based on Doppel level, we categorized them into Doppel-high (Dpl hi ) and Doppel-low (Dpl low ) groups. Using ascites-derived organoids and single cell sequencing of whole ascites of Dpl hi and Dpl low patients, we identify that Doppel induces epithelial-mesenchymal transition (EMT) and creates an immunosuppressive microenvironment, respectively. Doppel levels in the sera/ascites correlate with the changes of Dpl+ CTC number in whole blood, highlighting the association of Doppel-induced EMT with CTC dissemination in circulation. Thus, Doppel-based detection of EOC subtypes could be a promising platform as clinical biomarker and link Doppel-axis with OC dissemination.
Ovarian cancer remains a lethal gynecologic malignancy, with high-grade serous ovarian carcinoma (HGSOC) accounting for a large proportion of advanced-stage disease. HGSOC commonly disseminates across the peritoneal cavity, where malignant ascites contain tumour cells, stromal and immune cells, soluble mediators, and extracellular vesicles (EVs). Although epithelial–mesenchymal transition (EMT) has often been used to ex-plain invasive behaviour, tumour cells may occupy reversible hybrid epithelial/mesenchymal states rather than completing a uniform transition. This review synthesizes evidence linking EV-associated communication with epithelial–mesenchymal plasticity (EMP), peritoneal dissemination, and treatment resistance, with particular attention to the strength and context of the evidence. We distinguish endosome-derived exosomes from small EV (sEV) preparations whose biogenesis has not been established, and separate observational associations from functional experiments, animal-model findings, and clinical evidence. Our central contribution is an evidence-calibrated framework connecting EV biology, ascites-associated selection pressures, and dynamic cell states while identifying where causal mechanisms and clinical utility remain unproven. EV associated cargo and EV-targeting approaches are promising research directions, but neither biomarker performance nor therapeutic benefit should be considered clinically established without independent validation.